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Methamphetamine (Meth) is abused by over 35 million people worldwide. Chronic Meth abuse may be particularly
devastating in individuals who engage in unprotected sex with multiple partners because it is associated with a 2-fold
higher risk for obtaining HIV and associated secondary infections. We report the first specific evidence that Meth at
pharmacological concentrations exerts a direct immunosuppressive effect on dendritic cells and macrophages. As a
weak base, Meth collapses the pH gradient across acidic organelles, including lysosomes and associated autophagic
organelles. This in turn inhibits receptor-mediated phagocytosis of antibody-coated particles, MHC class II antigen
processing by the endosomal–lysosomal pathway, and antigen presentation to splenic T cells by dendritic cells. More
importantly Meth facilitates intracellular replication and inhibits intracellular killing of Candida albicans and
Cryptococcus neoformans, two major AIDS-related pathogens. Meth exerts previously unreported direct immunosup-
pressive effects that contribute to increased risk of infection and exacerbate AIDS pathology.
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Introduction
Chronic methamphetamine (Meth) abuse has reached
epidemic proportion throughout the United States, where a
2003 survey indicated that approximately 5% of the
population over 12 years of age has tried Meth and the rate
of treatment admissions for primary Meth abuse increased
over 3-fold (The DASIS Report, http://www.oas.samhsa.gov/
2k6/methTX/methTX.htm) [1,2]. In particular, among gay and
bisexual men [3] Meth it is associated with high-risk sexual
behavior, HIV viral infection, and a high incidence of AIDS
[4]. Meth exacerbates AIDS pathology, including cognitive
deﬁcits [5,6], and is strongly suspected to inhibit normal
immunological response to secondary infections such as
hepatitis C, which is prevalent in those who smoke or take
Meth intranasally [7]. It has recently been suggested that Meth
could contribute to a particularly rapid progression of AIDS
in individuals exposed to a strain of HIV that is resistant to
drug treatment [8,9]. Indeed, animal studies clearly demon-
strate that Meth suppresses both innate and adaptive
immunity [10,11], enhances cytokine production in combi-
nation with HIV TAT protein [12], and alters gene expression
in cells of the immune system [13]. However, the molecular
basis for Meth’s immune suppression is unknown. Here we
have examined the relationship between Meth and the
impairment of speciﬁc immune cell functions.
In the clinical setting, Meth abusing individuals who
present with opportunistic infections possess high blood
and tissue levels of the drug. Meth is generally self-
administered in this population in binges of 3–4 grams
ingested over a six day interval [14], with an initial ingestion
of ;0.5 gram (Judith Rabkin, Columbia University, personal
communication) and a total mean level of 2.2 grams ingested
during the ﬁrst day [15]. Such high levels of administration
result in a blood concentration of ;10–50 lM Meth, and
levels in the hundreds of micromolar range in organs
including brain and the spleen [16] (see Results).
Pathogens are processed and displayed by antigen present-
ing cells (APCs) for T cell recognition. Antigen presentation
in tissue resident macrophages, as well as dendritic cells,
involves ﬂuid phase or receptor-mediated endocytosis fol-
lowed by fusion of the phagosome with specialized lysosomes
known as MHC class II compartments (MIIC) [17]. The
foreign antigens are partially degraded by lysosomal hydro-
lases and the resulting peptides are loaded on MHC class II
molecules and transported to the cell membrane to be
presented to T cells. Both pathogen transport to the MIIC
and its degradation into immunogenic peptides are functions
that require an acidic endosomal pH. Endogenous antigens
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some fusion [18]. Autophagy also mediates single-stranded
RNA virus detection and consequent interferon-a release in
plasmacytoid dendritic cells activating anti-viral cellular
defense mechanisms in uninfected cells [19]. Further evi-
dence shows the direct role of autophagosomal-lysosomal
degradation in elimination of intracellular HSV-1 viral
particles [20] and that the HSV-1 has alternative methods
to counteract cellular autophagy [21].
In this study, we have identiﬁed a novel molecular
mechanism that explains the immunosuppressive effects of
Meth via the alkalization of acidic organelles in dendritic cells
and macrophages that are critical for the immunological
function of these APCs.
Results
Estimates of Pharmacological Meth Levels in Humans
To model effects of Meth on the immune system, we
estimated Meth levels in drug abusers. Meth is self-adminis-
tered intravenously, by nasal inhalation, anally, and orally, in
typical doses of 250–500 mg by occasional users to levels as
high as 1 g by chronic abusers (personal communication,
Perry N. Halkitis, New York University). Meth blood levels
measured in individuals detained by police in California were
2.0 lM on average but as high as 11.1 lM [22]. Controlled
studies indicate that a single 260 mg dose reaches a level of
7.5 lM [22]. Thus, a single dose of 260 mg – 1 g would be
expected to produce 7.5 – 28.8 lM blood Meth levels.
The abusers however tend to self-administer METH in
binges, and as the drug exhibits a half-life of 11.4 - 12 h
[23,24], this leads to higher levels. Recently published studies
modeling binge pattern of use in individuals show that after
the fourth administration of 260 mg during a single day
produces maximum blood levels of 17 lM, reaching 20 lMo n
the second day of such a binge [22]. Thus, binge doses of 260
mg – 1 g would produce 17 - 80 lM blood Meth levels. The
estimates appear consistent with blood levels detected after
fatalities [25–27], ranging as high as 84 lM for an individual
for whom Meth intoxication was determined as the cause of
death ;16 hours after ingestion.
It is also important to estimate how Meth is distributed
from blood to other tissues involved in immune response,
particularly the spleen, which houses high numbers of
dendritic cells. Tissue-to-serum Meth ratios in rat are: brain,
9.7; kidney, 35.3; spleen, 14.3 [16]. Thus, relevant levels in
spleen, the organ critical for immune response, after
administration of 250 mg – 1 g as a single dose is 100 – 400
lM, and during binges between 240 – 1144 lM.
Meth Induces Rapid Alkalization of Acidic Organelles and
Changes in Endosomal Morphology
Dendritic cell MIIC processing organelles are characterized
by acidic pH [28], a limiting membrane enclosing internal
vesicles or lamellae [17], the presence of proteases [29],
internal expression of LAMP [30] and MHC II proteins [31].
The morphological and functional integrity of the MIIC
depends on the maintenance of an acidic pH [32] due to the
action of the V-ATPase, which may also regulate transport
from early to late endosomes and lysosomes [33]. Meth and its
metabolite, amphetamine, are membranophilic weak bases
that collapse intracellular organelle pH gradients in neurons
[34,35]. We therefore tested whether Meth collapsed intra-
cellular organelle pH gradients in dendritic cells by monitor-
ing quenching of acridine orange, a weak base vital dye that
accumulates in acidic organelles including endosomes and
lysosomes [35]. We found that Meth concentrations of 50 lM
or higher rapidly collapsed acidic organelle pH gradients in
dendritic cells (Figure 1A–1B). LysoSensor Yellow/Blue
ratiometry is a generally accepted method to measure
organellar pH in live cells, and was used to measure average
pH in acidic organelles using LysoSensor Yellow/Blue
ﬂuorescent dye. After 10 min treatment with Meth (50 or
100 lM) or chloroquine (10 lM) acidic organellar pH was
elevated (pH 6.5, 6.9 and 6.4 respectively) signiﬁcantly above
the levels in untreated control cells (pH 4.8) (Figure 1C). As
predicted with alkalizing agents, Meth also disrupted MIIC
structure [36], producing large organelles (. 1 lm diameter)
devoid of internal vesicles (right panels) with LAMP-1 and
MHC II staining conﬁned to the limiting membrane (Figure
1D and 1E). Chloroquine (Clq) [10 or 20 lM], another weak
base was used as a control showed similar effects to Meth as
described above (Figure 1A–1E). At the used concentrations
(20 and 100 lM) Meth did not affect cell viability as
determined by ﬂow cytometric analysis (Figure S1).
Meth Inhibits Endosomal Antigen Processing and MHC II
Restricted Antigen Presentation
To investigate whether Meth-induced endosomal alkaliza-
tion blocks antigen processing by impairing dendritic cell
lysosomal proteolytic degradation of foreign proteins, we
exposed cells to the ﬂuorescently labeled MHC II antigens
[bovine serum albumin (BSA), casein, and ovalbumin (OVA)],
and measured the degradation of each protein by western
blot. In untreated cells, each antigen was proteolytically
degraded, while antigen degradation was blocked in Meth or
Clq treated cells (Figure 2A and 2B). Meth (10, 50, 100 lM)
and Clq (10, 20 lM) effectively inhibited processing of
antigens previously taken up by dendritic cells (Figure 2A).
Control experiments showed that Meth did not block
endocytosis of 2 lm ﬂuorescent dextran beads by dendritic
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Author Summary
There is a new population of HIVþ men who are developing AIDS
over months instead of years as typical. It has recently become
popular among gay and bisexual men to consume very high levels
of Meth. Unsafe sex together with Meth abuse has been suspected
to lead to rapid disease progression. While studies show exacer-
bated AIDS symptoms and disease progression in HIVþ Meth
abusers, the molecular mechanism is yet unknown. It was
postulated, yet unproven, that the rapid disease progression might
be due to a mutant ‘‘superstrain’’ of HIV that was extremely virulent.
It was also assumed that the effects of the drug on behavior may
lead to unsafe sex, although this would not explain the more rapid
time course of the disease. We now demonstrate the first direct
evidence that Meth is an immunosuppressive agent, and that the
molecular mechanism of this immunosuppression is due to the
collapse of acidic organelle pH in cells of the immune system,
inhibiting the functions of antigen presentation, as well as
phagocytosis. These effects compromise the immune response to
opportunistic infections and HIV. These findings could have a major
impact on public health, as there are over 35 million Meth abusers
worldwidecells (Figure S2), indicating that the drug does not inhibit
nonspeciﬁc phagocytosis [37] .
To determine the stage at which Meth compromised post-
endocytic proteolytic antigen processing, we prepared
fractions of early and late endosomes and lysosomes from
dendritic cells exposed to BSA and casein antigens. Each
fraction was examined for b hexosaminidase to identify
lysosomes and late endosomes, the transferrin receptor
(TrfR) to identify early endosomes, and LAMP-1 to identify
late endosomes and lysosomes (Figure 2C and 2D). No
detectable antigen remained in early endosomes under any
of these conditions. There were, however, much higher levels
of BSA and casein in lysosomes and late endosomes of Meth-
and Clq-treated cells than in controls. In particular, casein
was completely degraded in untreated cells but relatively
unprocessed in dendritic cells treated with Meth or Clq
(Figure 2E). Thus, Meth inhibited antigen proteolysis within
late endosomal/lysosomal compartments. Similarly, process-
Figure 1. Meth Induces Rapid Alkalization of Acidic Organelles, and Changes in Endosomal Structure in Dendritic Cells
(A) Morphometric analysis of the decrease in acridine orange staining after 10 min treatment. Similar results were obtained in three independent
experiments. (Statistics n ¼ 25–35, mean 6 SEM, **p , 0.001, ***p , 0.0001, two-tailed ANOVA.)
(B) Progressive quenching of cytosolic acridine orange staining over 4 h in the absence (&) or presence (m)o f5 0lM Meth. p , 0.001 for all time points
versus control (n ¼ 25–35, mean 6 SEM, Student’s two-tailed t-Test).
(C) Acidic organelle pH in cells exposed to Meth for 10 min measured by ratiometric measurement. (Statistics n¼30–90 cells, mean 6 SEM, **p , 0.001,
***p , 0.0001, two-tailed ANOVA.)
(D) Representative electron micrographs showing multivesicular endosomal compartments (arrows) in control, Clq- and Meth-treated cells at 4 h. Scale
bar, 200 nm. (E) Ultra-thin cryosections of control, Clq- and Meth-treated dendritic cells as in (D), immunolabeled for LAMP-1 (15 nm gold particles) and
MHC class II (10 nm gold particles). Scale bar, 200 nm.
doi:10.1371/journal.ppat.0040028.g001
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Methamphetamine Inhibits Immune Responseing of invariant chain was compromized after Meth treatment
as indicated by increased levels of p25/28 and p10 fragments
during the chase time-point (Figure 2F).
MHC II antigen presentation stimulates T cell prolifer-
ation, providing a means to measure effects of Meth on
antigen presentation. We prepared cultures of immature
bone marrow-derived dendritic cells and splenic puriﬁed T
cells, both from OTII transgenic mice [38]. Using OVA as an
antigen, we assayed cellular proliferation of T cells by
radiolabeled thymidine uptake and incorporation into
DNA. At all levels tested, Meth decreased the T cell
proliferative response to the intact antigen (Figure 2G) but
not the pre-processed OVA-323–339 peptide (Figure 2H).
Autophagosome Accumulation Is Induced by Meth
In addition to blocking lysosomal antigen degradation,
Meth could disrupt processing and presentation of antigens
by inhibiting autophagosome formation, thereby halting
antigen delivery to MIIC. To test this possibility, we prepared
dendritic cells from a transgenic mouse expressing a GFP-
fused autophagosome-associated protein LC3 (GFP-LC3)
which has been used as an in vivo autophagosomal marker
[39]. Consistent with previous reports in neurons [40], 50–500
lM Meth induced autophagosome accumulation in dendritic
cells (Figure 3A–3C). Our data show that Meth does not block
autophagosome formation, but rather impairs lysosomal-
autophagosomal degradation, resulting in the accumulation
of autophagosomes, and impaired intracellular antigen
proteolysis. Together with the evidence from endosomal/
lysosomal fractions (Figure 2C–2E), these results strongly
suggest that Meth inhibits degradative antigen processing by
disrupting pH gradients.
Meth Alkalizes Acidic Organelles and Induces
Autophagosome Formation in Macrophages
As with dendritic cells, we also found that Meth and Clq
effectively collapsed the intracellular pH gradients within
macrophages (Figure S3A–S3C) and blocked autophagosome
degradation, resulting in the accumulation of GFP-LC3
labeled autophagosomes (Figure S4A–S4D). Similar results
were obtained with the ﬂuorescent dye monodansylcadaver-
ine, a lipophilic weak base that accumulates in lysosomes and
autophagosomes (Figure S4E).
Meth and Clq Inhibit Phagocytosis in Macrophages
Since Meth users can also present with bacterial infections
[41], we examined whether Meth disrupts macrophage
phagocytosis, a primary mechanism for clearance of these
extracellular pathogens. Murine peritoneal-derived macro-
phages were incubated in the presence or absence of Meth.
After 2 h, IgG-antibody coated erythrocytes [E(IgG)] were
added to each of the conditions and the number of ingested
erythrocytes counted. We found that Meth (50 and 250 lM)
inhibited E(IgG) phagocytosis (Figure 4A and 4B) by 20 and
45%, respectively. Meth did not inhibit the receptor-
independent endocytosis of Lucifer Yellow (Table S1). Similar
effects were observed with Clq (Figure 4A and 4B) These
results demonstrate that Meth inhibits Fcc-mediated phag-
ocytosis in macrophages and are consistent with the
observations that the macrophage Fcc receptors are contin-
uously recycled between phagosomes and the plasma mem-
brane [42], a process that requires appropriate acidiﬁcation
of secretory vesicles and tubules for trafﬁcking [43]. These
results demonstrate that Meth inhibits Fcc-mediated phag-
ocytosis in macrophages.
Meth and Clq Inhibit Macrophage Phagocytosis and
Intracellular Replication of Candida albicans and
Cryptococcus neoformans
As a next step we analyzed the effects of Meth on Candida
albicans (Ca) and Cryptococcus neoformans (Cn) phagocytosis and
killing by murine macrophages since these two organisms are
the most commonly isolated fungi in individuals infected with
HIV [44]. Clq and Meth (10 and 50 lM) inhibited phagocytosis
of Ca and Cn by macrophages by 40% (Figure 4C). Moreover,
Meth enhanced the proliferation of fungi within macro-
phages (Figure 4D), indicating that intracellular replication of
both yeast was facilitated by Meth. In contrast, Clq had no
signiﬁcant, or slightly reducing, effect on Ca (p¼ 0.056) and
Cn (p ¼ 0.060) CFU numbers in macrophages. Control
experiments showed that in the absence of macrophages, Ca
and Cn proliferation was unaffected by the addition of Clq or
Meth to the BHI medium (data not shown).
Meth-Treated HIV-Infected Macrophages Exhibit Increased
p24 Secretion
To further examine why chronic Meth abuse has been
recently associated with the rapid development of immune
deﬁciency among gay and bisexual men [3], we studied the
effect of Meth on HIV proliferation in macrophages from
HIV-transgenic mice. These JR-CSF/huCycT1 double trans-
genic mice express HIV-1 JR-CSF, which is a full length R5
HIV-1 provirus regulated by the endogenous HIV-1 LTR, as
well as the human cyclin T1 controlled by a murine CD4
expression cassette [45]. These mice have constitutive HIV
production in CD4 T lymphocytes and monocytes. GM-CSF
differentiated bone marrow cells were either left untreated or
treated with a range of Meth levels (10, 50, 150 lM) or NH4Cl
(A) Western blots of bone marrow derived dendritic cells which phagocytosed FITC-labeled BSA, casein or OVA overnight, and exposed to Clq or Meth.
Unprocessed antigens are quantified using anti-FITC mAb.
(B) Densitometric analysis of western blots for the amount of unprocessed intracellular antigen. Representative of two to three independent
experiments.
(C) b-hexosaminidase activity measured in sub-cellular fractions to identify lysosomes and late endosomes.
(D) Western blot using LAMP-1 and TrfR mAb on lysosomal, as well as early and late endosomal fractions.
(E) Western blot analysis of the above pulled fractions from untreated, Clq- or Meth-treated dendritic cells using anti-Fitc mAb.
(F) Immunoprecipitation of invariant chain in pulse-chase experiments. Full length invariant chain (p31) and degradation products (p25/28 and p/10) are
indicated.
(G) T cell proliferative response to bone marrow derived dendritic cells cultured with OVA protein (0, 3, 10, and 30 lM) in the absence (Ctr *)o r
presence of Meth (10 *,5 0u, 100 lM n) or Clq (5 &,1 0lM m) for 6 h, and cultured with T cells for 3 d. [
3H]-Thymidine incorporation was used to assay
T cell proliferation. (Statistics n ¼ 4, mean 6 SEM, **p , 0.001, two-tailed ANOVA.)
(H) T cell proliferative response to bone marrow derived dendritic cells cultured with OVA peptide 323–339 (0, 3, 10, and 30 lM) in the absence (Ctr *)
or presence of Meth (10 *,5 0u, 100 lM n) or Clq (5 &,1 0lM m) for 6 h, and cultured with T cells for 3 d.
doi:10.1371/journal.ppat.0040028.g002
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were then collected and p24, a secreted HIV-speciﬁc protein,
was quantiﬁed by Elisa. Cells from JR-CSF/huCyc T1 mice
treated with Meth for 7 or 9 days exhibited a 30–60% increase
(Figure S5A) of p24 antigen production. Clq does not provide
a positive control, since its well-established inhibition of HIV
production is probably due to inhibition of viral capsid
protein glycosylation in the Golgi [46]. Thus, in this experi-
ment NH4Cl was used as positive control (Figure S5A).
To determine whether HIV replication was affected by
Meth in vivo, we studied the effect of Meth on HIV virus
proliferation in the JR-CSF/huCycT1 double transgenic mice
[45]. Mice were treated with increasing concentration of Meth
over a 7 day-period. One group of animals received 5 mg/kg
of Meth at day 0, 2 and 4 and was sacriﬁced at day 6 (low
Meth). Another group received 6 mg/kg at day 0; 7 mg/kg at
day 2 and 7.5 mg/kg at day 4 (high Meth) and was also
sacriﬁced at day 6. Copy number of HIV-1 RNA was
quantiﬁed in the serum of each mouse by RT-PCR using
primers spanning the highly conserved region of the HIV-1
gag gene. No statistically signiﬁcant differences were ob-
served between the untreated and the Meth-treated mice
(Figure S5B). These data suggest that Meth treated HIV-1
transgenic mice do not exhibit an increase in HIV viral load.
Discussion
We ﬁnd that the widely abused addictive psychostimulant,
Meth, at pharmacologically relevant levels acts as an
immunosuppressive agent, due to its inhibition of endosomal
acidiﬁcation. These actions result in Meth’s inhibition of
antigen presentation and phagocytosis. Maintenance of low
endosomal and lysosomal pH serves many functions, includ-
ing regulation of protein degradation, pathogen inactivation,
and regulation of the amount of several surface receptors. All
of these functions require active transport via the endocytic
pathway and fusion with lysosomal compartments.
First, via alkalization, METH-inhibited lysosomal-autopha-
gosomal degradative function for both exogenously and
endogenously internalized antigens resulting in accumulation
of proteins entering the endocytic pathway through phag-
ocytosis, as well as autophagic vacuoles. Chaperone-mediated
Figure 3. Meth Induces Autophagosome Accumulation in Dendritic Cells
(A) Accumulation of GFP-LC3 labeled autophagosomes in Meth- or Clq-treated dendritic cells at 2 h and 24 h. Fisher’s exact test P values versus control
(n ¼300–400 cells, mean 6 SEM, *p , 0.05, ***p , 0.0001).
(B) GFP-LC3 labeled autophagosome formation in different concentrations of Meth after 24 h treatment. Similar results were obtained in three
independent experiments. Fisher’s exact test versus control (n ¼ 300–400 cells, mean 6 SEM, ***p , 0.0001).
(C) Representative fluorescence micrographs of GFP-LC3 decorated autophagosomes in cells treated with 50 lM Meth or 10 lM Clq for 24 h. Arrow
denotes examples of autophagosomes. Scale bar, 10 lm.
doi:10.1371/journal.ppat.0040028.g003
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described as major pathways for endogenous antigen pro-
cessing in MHC class II compartments [18,47,48] and as a
means to directly degrade intracellular virus particles [20,21].
Thus, through its alkalizing effect, Meth blocks normal
antigen processing and presentation. Progression of inter-
nalized antigens along the endocytic pathway rely on the
progressive maturation of early endosomes into late endo-
somes and ultimately to lysosomes. Maintenance of an acidic
internal pH and a pH gradient in these compartments is
important for the cargo progression. Endosomal acidiﬁcation
is accomplished by H
þ transport across the endosomal
limiting membrane by the proton pump vacuolar ATPase
(V-ATPase). The recent discovery that V-ATPase interacts
with components of the endocytic transport machinery
indicates that V-ATPase is also a pH sensor that regulates
early to late endosomal transport [33]. This would explain
why endosomal alkalization by Meth not only disrupts antigen
processing but phagocytosis and cargo progression along the
endosomal pathway.
Figure 4. Meth and Clq Inhibit Phagocytosis in Mouse Peritoneal Macrophages
(A) Cells were incubated in indicated concentrations of Meth or Clq for 2 h, and then IgG coated erythrocytes were added. Extracellular uningested EIgG
were lysed and removed. Phagocytic index (PI) was quantified and inhibition is indicated as percent of control. Data were collected from four to seven
experiments (n ¼ 300 cells, mean 6 SEM, ***p , 0.0001, two-tailed ANOVA).
(B) Images of macrophage cells impaired in the phagocytosis of opsinized sheep erythrocytes after 2 h of Meth or Clq treatment. Arrows denote
phagocytosed erythrocytes. Scale bar, 10 lm.
(C, D) J774.16 cells were exposed to PBS, chloroquine, or methamphetamine for 2 h followed by incubation with Cn or Ca. The phagocytic indices (ratio
of intracellular yeast to the number of macrophages counted) were determined after 1 h or 30 min for Cn and Ca, respectively (C). (Statistics n ¼300,
mean 6 SEM, *p , 0.05, two-tailed ANOVA.) CFU determinations were preformed after 24 h incubations (D). The values are the mean and standard
deviation from determinations made in triplicate wells (n ¼ 300 cells, mean 6 SEM, *p , 0.05, two-tailed ANOVA.). Experiments were repeated three
times with similar results.
doi:10.1371/journal.ppat.0040028.g004
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Cn phagocytosis and killing by macrophages. These effects are
expected to be particularly devastating in AIDS-related
disorders, since Ca and Cn are the two most commonly
isolated fungi from sterile body ﬂuids obtained from HIV
infected individuals [44]. Also, these results could explain
recent reports of rapid insurgence of AIDS in Meth-addicted
individuals soon after infection with HIV. Thus, Meth also
blocks pathogen killing by macrophages. Exposure to Clq and
other weak bases was already been shown to inhibit growth of
Cn in macrophages [49,50] even though Clq has no direct
toxicity to Cn [50]. Not all basic compounds are equivalent in
their fungicidal activity; for example, ammonium chloride
also enhances the anti-cryptococcal activity of macrophages,
yet the potency of ammonium chloride is less than that of
Clq, which may be a result of the ability of ammonium
chloride to inhibit phagolysosomal fusion [51]. Hence, Meth
apparently has complex effects on macrophages that result in
an intracellular milieu that enables the replication of the
examined pathogenic fungi.
Third, even though an increase in p24 secretion has been
observed in Meth-treated dendritic cells and macrophages, a
direct effect of Meth on HIV viral load could not be
demonstrated. It is likely that viral proteins enter late
endosomal and lysosomal compartments independently of
viral assembly, and due to inhibition of processing, more viral
proteins are secreted in the extracellular milieu. Within the
infected macrophages, HIV has been previously shown to
assemble in compartments with characteristics of multi-
vesicular late endosomes (CD63, Lamp-1, CD81 and CD82
positive) [52]. It now appears that the HIV particles present in
multivesicular endosomes are the results of endocytosis, and
the site of viral assembly is at the invagination of the plasma
membrane particularly enriched in tetraspannin proteins
[53]. These results would explain why, by compromising
endosomal pH, an increase in HIV viral load has not been
observed.
In conclusion, the immunosuppressive effects of Meth are
consistent with reports that Meth-treated mice demonstrate
decreased immunity [10,11]. To be noted is that even though
there is a linear concentration-dependent response between
Meth concentration and pH disruption such an effect is less
evident at the biological level. In all assays (antigen process-
ing, Ca or Cn killing and p24 production) different Meth
dosages behave very similarly. Likely a small disruption in the
endosomal pH is sufﬁcient to alter the microenvironment
and endosomal-related functions. This is consistent with the
effects of low concentrations of Meth tested on lysosomal pH
in Figure 1C, with alkalinization of . 1 pH unit, which would
effectively inhibit lysosomal protease activity.
The collapse of endosomal pH by Meth and the resulting
decrease of normal immune response provide an explanation
for the compromised immunity and exacerbate infections
occurring in Meth abusers. In fact, Meth is strongly suspected
to more dramatically inhibit normal immune responses than
other drugs of abuse since Meth users often present with skin
lesion and ‘‘Meth mouth’’, a devastating periodontal disease
(http://www.drugfree.org/) [54] and [1,2]. A similar immuno-
suppressive activity has also been shown for chloroquine, also
a well known inhibitor of endosomal acidiﬁcation [36].
In particular, Meth immunosuppression may underlie the
mechanism of the recently reported extremely rapid develop-
ment of immune deﬁciency, with devastating effects in AIDS-
related disorders in Meth abusers that had contracted HIV. In
particular, there is evidence suggesting the presence of a new
population of HIV
þ positive men who are developing AIDS
over months rather than over 10 or more years as is typical.
The most widely reported individual was documented by Dr.
Martin Markowitz of the Aaron Diamond AIDS Research
Center in New York in 2004. In this individual, a gay man who
was also a Methabuser tested HIV negative in May, 2003, then
likely contracted HIV during unprotected sex in mid-
October 2004, displayed acute retroviral syndrome in
November, 2004 and 3-drug-class-resistant HIV-1 (3DCR
HIV) with apparently rapid progression to AIDS by Decem-
ber, 2004 (CDC, MMWR July 28, 2006/55(29);793–796). Meth
self-administration by HIVþ individuals during the acquis-
ition of sexually transmitted pathogens appears likely to
interfere with immunological resistance and lead to AIDS
progression.
Materials and Methods
Additional detailed methods used in this paper can be found in
Protocol S1.
Primary cell culture. Mouse femur hematopoietic stem cells from
bone marrow were harvested from the hind legs of 8 to 12-week old
male wild-type C57BL/6J (The Jackson Laboratory, Bar Harbor,
Maine) or GFP-LC3 transgenic mice [39], and plated at 2 3 10
6 cells/
ml density in DMEM supplemented with 10% FBS, 1x non-essential
amino acids (Gibco, Carlsbad, California), 2 mM L-glutamine, 1 mM
sodium pyruvate and 20 mM HEPES. For differentiation to dendritic
cells or macrophages, 10 ng/ml of recombinant mouse GM-CSF
(Biosource, Carlsbad, California) or 10 ng/ml of recombinant mouse
M-CSF (R&D Systems, Minneapolis, MN) was added to media,
respectively. Cells were fed every 2 days with fresh DMEM containing
the appropriate macrophage colony stimulating factor. Cells were
trypsinized after 8 days and, unless otherwise noted, plated at 4310
5
cells/cm
2 density to be used for experiments the following day.
Resident mouse peritoneal macrophages were isolated from 8 to 12
week-old female wild-type C57BL/6J as described [55] and plated on
12 mm-diameter glass coverslips in 24-well tissue culture plates at 33
10
5 cells/well density in RPMI media supplemented with 10% FBS
with streptomycin and penicillin. Non-adherent cells were removed
by washing 2 h after plating. The remaining adherent cells were over
95% macrophages as assessed by esterase staining [55]. Cells were
incubated overnight prior to experiments.
Morphometric analysis of acridine orange staining. Cells were
stained with 10 mM acridine orange in phenol red-free media for 1 h.
Images of stained cells were acquired using ﬂuorescence microscopy
as described above. Images of 10 ﬁelds with 5 to 10 cells for each
image were taken using multiple stage positions in Multidimensional
Acquisition mode under conditions of no photobleaching (ND2 ﬁlter,
1000 msec exposure) that enabled the acquisition of multiple images
of the same cells. Stage position for each image was stored so images
of the same ﬁelds and cells could be taken before and after treatment.
Phenol red-free media containing 10 mM acridine orange in the
presence or absence of Meth or Clq was added to the cells. At the end
of the incubation time, images of treated cells were taken and used
for morphometric analysis. Change in acridine orange intensity was
measured as a change in average pixel intensity in the cytoplasmic
area using MetaMorph Version 6.1r6 image analysis software
(Molecular Devices, Sunnyvale, CA). Background mean pixel intensity
was measured in nuclear area and subtracted.
Ratiometric measurement of acidic organelle pH. Dendritic cells
were stained with 5 lM LysoSensor Yellow/Blue (Invitrogen, Carlsbad,
CA) for 5 min before Meth (10, 50, 100 lM) or Clq (10lM) was added
for an additional 10 min incubation followed by washing with
phosphate-buffered saline (PBS) (pH 7.4). Fluorescent images were
taken of the same cells using Olympus IX81 microscope with
Photometrics CoolSNAP HQ cooled camera, MetaMorph Version
6.1r6 imaging software (Molecular Devices, Sunnyvale, CA), Olympus
PlanApo 40x/1.4 Oil objective, equipped with ﬂuorescent yellow
customized Chroma (D350/50 excitation, 400DCLP dichroic splitter
and D535/40m emission) (Chroma technology Corp., Rockingham,
VT) and blue Chroma 31000v2 (D350/50 excitation, 400DCLP
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intensity was measured in the cytoplasm of the cells excluding the
nucleus using MetaMorph software, and the ratio of yellow to blue
intensity was compared to a pH calibration curve to determine pH
values. For the calibration curve, cells were stained with 5 lM
LysoSensor Yellow/Blue for 20 min, washed with PBS and incubated
in buffer of known pH (4.0 to 7.4) containing 10 lM monensin and 10
lM nigericin [56] before images were taken and processed as above.
Ultrastructural analysis and immunogold labeling. Dendritic cells
were derived and incubated for 4 h with or without Clq (20 lM) or
Meth (100 lM). Cells were ﬁxed in 2% paraformaldehyde and 2.5%
glutaraldehyde in 0.1 M sodium cacodylate buffer, postﬁxed with 1%
osmium tetroxide followed by 1% uranyl acetate, dehydrated through
a graded series of ethanol and embedded in LX112 resin (LADD
Research Industries, Williston, VT). Ultrathin (80 nm) sections were
cut on a Reichert Ultracut UCT, stained with uranyl acetate followed
by lead citrate and viewed on a JEOL 1200EX transmission electron
microscope at 80 kV.
For immunogold labeling, cells treated as described above were
ﬁxed in 2% paraformaldehyde and 4% polyvinylpyrolodone in
phosphate buffer 0.2 M (pH 7.4) at 4 8C. Fixed cells were processed
for ultrathin cryosectioning as previously described [14]. Immunogold
labeling was performed using LAMP-1 antibody (clone 1D4B, BD
Pharmingen, San Diego, CA) followed by anti rat Ig-G coupled with 10
nm gold particles and biotinylated anti-MHC II (clone M5/114.15.2,
BDPharmingen, SanDiego,CA) followedby streptavidingold(15 nm).
Contrast was obtained with a mixture of 2% methylcellulose (Sigma,
St. Louis, MO) and 0.4% uranyl acetate pH 4 (EMS, Hatﬁeld, PA).
Antigen processing. FITC-coupled BSA, ovalbumin or casein were
fed to immature bone marrow-derived dendritic cells (between 1 to 3
3 10
7 cells for each condition) at a concentration of 100 lg/ml. Cells
were untreated or treated with Meth or Clq. After overnight
incubation, cells were washed twice in PBS and lysed in 150 mM
NaCl, 50 mM Tris-HCl and 1% NP40 supplemented with protease
inhibitor cocktail. Post-nuclear supernatants were normalized for
protein content and 80 lg of total protein was run on SDS-PAGE gel.
Membrane blots were probed with the anti FITC mAb or b-tubulin
mAb (Sigma, St. Louis, MO).
Sub-cellular fractionation. The immature bone marrow-derived
dendritic cell line JAWS (ATCC) was used for sub-cellular fractiona-
tion. One hundred million cells were used for each experimental
condition. Cells (4 3 10
6 cells/ml) were incubated overnight with 80
lg/ml of FITC-labeled BSA or casein in presence or absence of Clq
(20 lM) or Meth (50–100 lM). Cells were then lysed in 250 mM
sucrose, 1 mM EDTA pH 7.4. Early and late endosomes and lysosomes
were prepared over consecutive Percoll gradients (27% and 10%)
from cells treated as reported above [57]. Each fraction was tested for
b hexosaminidase to locate lysosomes and late endosomes. The late
endocytic marker Lamp-1 (clone 1D4B, BD Pharmingen, San Diego,
CA) and the early endosomes/plasma membrane marker transferrin
receptor (TrfR) (clone M-A712, BD Pharmingen, San Diego, CA) were
also used to assess the purity of the endosomal preparations. Pulled
fractions 3–6 from the 27% Percoll gradient (lysosomes), 2–5 from
the 10% Percoll gradient (late endosomes) and 7–10 from the 10%
Percoll gradient (early endosomes) were run on SDS-PAGE and
blotted membranes analyzed for FITC-labeled antigens as reported
above.
Pulse chase and immunoprecipitation. GM-CSF differentiated
bone marrow dendritic cells were cultured in methionine- and
cysteine-free medium complete DMEM media containing 5%
dialyzed serum for 1 h. Cells were then labeled with 0.2 mCi/ml
[
35S]-methionine (Perkin Elmer, Waltham, MA) for 30 minutes (pulse).
Cells were then washed three times and incubated in complete DMEM
media supplemented with 10X cold methionine for 4 hours (chase) in
the presence or absence of 50 lM Meth. Cells were subsequently lysed
in 1% NP40, 150 mM NaCl, 50 mM Tris containing a cocktail of
protease inhibitors (Complete Mini, Roche Diagnostics, Indianapolis,
IN) for 30 min on ice, spun at 14000 rpm for 30 minutes to remove
cell nuclei and debris. The amount of incorporated radioactivity in
each sample was determined by precipitating 10 ll of the post-
nuclear supernatants with 10% trichloroacetic acid (TCA). Equivalent
amounts of radioactive lysates were pre-cleared with rat serum
adsorbed to Prot G beads followed by Protein G beads alone, for 2
hours at 48C. Immunoprecipitation was performed using 10 lg of anti
CD74 (clone In-1, Pharmingen, San Diego, CA) bound to Protein G
beads. The beads were washed 3 times with lysis buffer and eluted
with sample buffer. The elute was boiled and resolved by SDS-PAGE.
The gel was subsequently dried and exposed in autoradiography.
Antigen presentation. Bone marrow-derived dendritic cells from
OT II transgenic mice (Jackson Laboratory, Bar Harbor, MN) were
grown in 10 ng/ml of mouse GM-CSF for 10–12 days. Splenic T cells
were puriﬁed using the pan-T cell isolation kit (Miltenyi Biotec,
Auburn, CA) according to the manufacturer’s suggestions. One
hundred thousand dendritic cells were cultured with 4 3 10
5 T cells
in the presence or absence of 0, 3, 10, and 30 lM OVA protein for 3
days at 378C. In some experiments Meth or Clq was added on the ﬁrst
day of culture until the end of the proliferative response. In other
experiments, dendritic cells were pretreated with Meth or Clq for 4 h
at 378C, washed and ﬁxed in 1% paraformaldehyde before adding
OVA 323–339 peptide and the T cells. In all experiments, [
3H]-
thymidine (1 lCi/well) was added during the last 18 h of incubation to
assay T cell proliferation. Plates were harvested and the DNA [
3H]-
thymidine incorporation was monitored using a Wallac liquid
scintillation counter (Perkin Elmer, Waltham, MA).
Autophagy assay in GFP-LC3 dendritic cells and macrophages.
Bone marrow-derived dendritic cells and macrophages from GFP-
LC3 animals were plated at 4 3 10
5 cells/cm
2 density in glass bottom
dishes and incubated overnight. Meth or Clq was added to the media,
and the cells incubated for 2 h and 24 h before ﬂuorescence
microscopy using an Olympus IX81 microscope with Photometrics
CoolSNAP HQ cooled camera, MetaMorph Version 6.1r6 imaging
software (Molecular Devices, Sunnyvale, CA), TC-324B Automatic
Temperature Controller (Warner Instrument Corporation, Hamden,
CT), Olympus PlanApo 60x/1.4 Oil objective, and a Chroma FITC
41001 (HQ480/40x excitation, Q505LP dichroic splitter and HQ535/
50m emission) (Olympus, Center Valley, PA) to determine GFP-LC3
puncta formation in the cells. At least 100 cell proﬁles per dish were
assayed in triplicate for GFP-LC3 puncta.
Macrophage phagocytosis assay and colony forming unit (CFU)
determination. Mouse peritoneal macrophages at 3.5 3 10
5 cells/cm
2
density on cover slips were incubated at 378C with 20 ll of IgG
opsinized sheep erythrocytes in 520 ll volume for 90 min. Uningested
erythrocytes were lysed by sequential washing with PBS, water, and
PBS. The phagocytic index was quantiﬁed by measuring the number
of erythrocytes phagocytosed per 100 macrophages using bright ﬁeld
microscopy and 20x magniﬁcation, and inhibition is identiﬁed as
percent of control. Data were collected from 4–7 independent
experiments. The average control phagocytic index was 433.
To determine the phagocytic index for Candida albicans (Ca) and
Cryptococcus neoformans (Cn) the macrophage like-cell line J774.16
(cultured in DMEM with 10% heat-inactivated FCS, 10% NCTC-109
medium, and 1% nonessential amino acids) was treated with 10 or 50
lM Methfor 2 h and then washed three times in media. As controls,
J774.16 cells were incubated in medium alone or in the presence of 20
lM chloroquine. Ca strain SC5314 yeast cells were grown in brain
heart infusion medium (BHI) at 378C for 24 h then washed three times
in PBS prior to application to macrophage. Cn yeast strain H99 was
grown for 24 h in BHI at 378C, incubated with capsule-speciﬁc
monoclonal antibody (mAb) 18B7 [58] as an opsonin at 10 lg/ml for 2
h and then washed three times in PBS prior to incubation with
macrophage. Ca and Cn cells were added to the macrophage
monolayer at an effector to target ratio 1:1, and the suspension was
incubated at 378C for 30 min with Ca or 1 h with Cn. After incubation,
remaining extracellular yeast cells were removed with three washes of
PBS. The phagocytic index was determined by microscopic examina-
tion. For each experiment, ﬁve ﬁelds in each well were counted, and at
least 100 macrophages were analyzed in each well. Wells were
performed in triplicate for each condition examined.
Colony counts were made to determine the number of viable Ca
and Cn yeast cells after phagocytosis. For the colony forming unit
(CFU) determination, J774.16 macrophages were treated with or
without Methor chloroquine and infected with Ca or Cn as described.
The cultures were washed after 2 h to remove extracellular yeast and
then incubated for an additional 22 h. After the 24 h total incubation,
macrophage cells were lysed by forcibly pulling the culture through a
27-gauge needle 5 times. The lysates were serially diluted, and plated
on Sabouraud dextrose agar at 378C. CFU determinations were made
after 72 h. Controls also consisted of yeast grown without macro-
phage, but in the presence of chloroquine or methamphetamine. All
tests were preformed in triplicate.
Supporting Information
Figure S1. Meth Does Not Affect Cell Viability
Bone marrow-derived dendritic cells were treated with Meth (100 lM)
or ethanol for 2 h at room temperature. Cells were then analyzed by
ﬂow cytometry for changes in cellular shape or granulosity both
indicators of cell death. No differences in shape, morphology or
granulosity were observed following Meth treatment.
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Figure S2. Meth Does Not Affect Fluid Phase Phagocytosis
Bone marrow-derived dendritic cells pre-treated with Meth or Clq for
2 h or left untreated were incubated for 30 min with PE-conjugated 2
lm ﬂuorescent dextran microbeads with a cell-bead ratio of 1:100.
The efﬁciency of the uptake was quantiﬁed by ﬂow cytometry.
Numbers in each quadrant refer to percentage of cells that have
internalized 0, 1, 2, and 3 or more beads (from left to right).
Found at doi:10.1371/journal.ppat.0040028.sg002 (2.6 MB TIF).
Figure S3. Meth Induces Rapid Alkalization in Acidic Organelles in
Macrophages
(A) Representative ﬂuorescence microscopy images of bone marrow-
derived macrophages with reduced acridine orange staining follow-
ing 10 min of Meth exposure Clq treatment. Scale bar, 10 lm. (B)
Morphometric analysis of the decrease in acridine orange staining
indicating alkalization upon 10 min treatment with Meth or Clq.
Similar results were obtained in three independent experiments (n¼
25–35, mean 6 SEM, *p , 0.01, ***p , 0.0001, two-tailed ANOVA).
(C) Progressive change in acridine orange label in the absence (&)o r
presence (m)o f5 0lM Meth. p , 0.001 for all time points versus
control (n ¼ 25–35, mean 6 SEM, Student’s two-tailed t-Test).
Found at doi:10.1371/journal.ppat.0040028.sg003 (5.6 MB TIF).
Figure S4. Meth Induces Autophagosome Accumulation in Macro-
phages as Lysosomal pH Is Alkalized
(A) Progressive accumulation of GFP-LC3 positive autophagosomes
in Meth- and Clq-treated cells at 2 h and 24 h. (n¼300–400, mean 6
SEM, **p , 0.001, ***p , 0.0001, Fisher’s exact test.) (B) GFP-LC3
labeled autophagosome formation in different concentrations of
Meth after 24 h treatment. Similar results were obtained in three
independent experiments. (n¼300–400, mean 6 SEM, ***p , 0.0001,
Fisher’s exact test.) (C) Fluorescence micrographs of GFP-LC3
decorated autophagosomes in cells treated with Meth or Clq for 24
h. Arrow denotes examples of autophagosomes. Scale bar, 10 lm. (D)
Phagosomes and autophagosomes labeled by GFP-LC3, in untreated,
Meth- or Clq-treated (2 h) mouse peritoneal macrophages phagocy-
tosing sheep erythrocytes. Red arrows denote representative auto-
phagosomes, while yellow arrows denote representative phagocytosed
erythrocytes. Scale bar, 10 lm. (E) Morphometric analysis of
monodansylcadaverine label in peritoneal macrophages after 24 h
treatment with Meth (n¼30, mean 6 SEM, ***p , 0.0001, two-tailed
ANOVA).
Found at doi:10.1371/journal.ppat.0040028.sg004 (4.8 MB TIF).
Figure S5. P24 Production Is Increased in Meth-Treated JR-CSF/
huCycT1 Monocytes
(A) Bone marrow dendritic cells from JR-CSF/huCycT1 mice were
incubated with or without different concentration of Meth or NH4Cl.
Supernatant was collected at day 7 and amount of secreted p24
measured. (Statistics n ¼ 4 dishes, mean 6 SEM, *p , 0.05, **p ,
0.001, two-tailed ANOVA.) (B) JR-CSF/huCycT1 mice were left
untreated or treated for one week with different amounts of Meth
(low and high as described in materials and methods). Sera collected
from each mouse were tested for amount of HIV-1 RNA using RT-
PCR. The values are the mean and standard deviation from the values
obtained from ﬁve mice in each group sample (n¼5 animals, mean 6
SEM, two-tailed ANOVA).
Found at doi:10.1371/journal.ppat.0040028.sg005 (2.1 MB TIF).
Protocol S1. Supporting Methods
Found at doi:10.1371/journal.ppat.0040028.sd001 (41 KB DOC).
Table S1. Fluid-Phase Phagocytotic Uptake of Lucifer Yellow (LY) Is
Unaffected by Meth and Clq Treatment in Mouse Peritoneal
Macrophages
Found at doi:10.1371/journal.ppat.0040028.st001 (1.6 MB TIF).
Acknowledgments
We thank Judith Rabkin (Columbia University) and Perry N. Halkitis
(New York University) for information on patterns of recreational
Meth use; Ana Maria Cuervo (Albert Einstein College of Medicine) for
discussion of potential roles for autophagic pathways in antigen
processing; Yvonne Schmitz, Kristine Larsen and Kim Atyeh for
comments on the manuscript.
Author contributions. The experiments were planned, performed,
and analyzed jointly by ZT, JL, DS, and LS. JM, DJ, YR, AG, and ST
performed the experiments. The GFP-LC3 mouse was constructed by
NM. NM, JN, and HG contributed reagents/materials/analysis tools.
DS and LS conceived and designed the experiments. The paper was
written by ZT, JL, DS, and LS.
Funding. This work was supported by National Institute on Drug
Abuse and the Parkinson’s Disease Foundation (DS), the Einstein/
Monteﬁore Medical Center for AIDS Research (LS), National
Institutes of Health (LS) and Irene Diamond Professorships in
Immunology (LS).
Competing interests. The authors have declared that no competing
interests exist.
References
1. Drug and Alcohol Services Information System (2006) Trends in
methamphetamine/amphetamine admissions to treatment: 1993–2003.
Available: http://www.oas.samhsa.gov/2k6/methTX/methTX.htm. Accessed
12 June 2007.
2. Colfax G, Shoptaw S (2005) The methamphetamine epidemic: implications
for HIV prevention and treatment. Curr HIV/AIDS Rep 2: 194–199.
3. Urbina A, Jones K (2004) Crystal methamphetamine, its analogues, and HIV
infection: medical and psychiatric aspects of a new epidemic. Clin Infect
Dis 38: 890–894.
4. Ellis RJ, Childers ME, Cherner M, Lazzaretto D, Letendre S, et al. (2003)
Increased human immunodeﬁciency virus loads in active methamphet-
amine users are explained by reduced effectiveness of antiretroviral
therapy. J Infect Dis 188: 1820–1826.
5. Carey CL, Woods SP, Rippeth JD, Gonzalez R, Heaton RK, et al. (2006)
Additive deleterious effects of methamphetamine dependence and
immunosuppression on neuropsychological functioning in HIV infection.
AIDS Behav 10: 185–190.
6. Cherner M, Letendre S, Heaton RK, Durelle J, Marquie-Beck J, et al. (2005)
Hepatitis C augments cognitive deﬁcits associated with HIV infection and
methamphetamine. Neurology 64: 1343–1347.
7. Gonzales R, Marinelli-Casey P, Shoptaw S, Ang A, Rawson RA (2006)
Hepatitis C virus infection among methamphetamine-dependent individ-
uals in outpatient treatment. J Subst Abuse Treat 31: 195–202.
8. (No Authors Listed) (2005) Meth’s impact on HIV epidemic being studied.
Drug’s use is growing problem among MSMs. AIDS Alert 20: 79–80.
9. Torian LV, Blank S, Kellerman SE, Frieden TR, Ho DD, et al. (2006)
Investigation of a new diagnosis of multidrug-resistant, dual-tropic HIV-1
infection–New York City, 2005. MMWR Morb Mortal Wkly Rep 55: 793–
796.
10. Yu Q, Zhang D, Walston M, Zhang J, Liu Y, et al. (2002) Chronic
methamphetamine exposure alters immune function in normal and
retrovirus-infected mice. Int Immunopharmacol 2: 951–962.
11. In SW, Son EW, Rhee DK, Pyo S (2005) Methamphetamine administration
produces immunomodulation in mice. J Toxicol Environ Health A 68:
2133–2145.
12. Theodore S, Cass WA, Maragos WF (2006) Involvement of cytokines in
human immunodeﬁciency virus-1 protein Tat and methamphetamine
interactions in the striatum. Exp Neurol 199: 490–498.
13. Mahajan SD, Hu Z, Reynolds JL, Aalinkeel R, Schwartz SA, et al. (2006)
Methamphetamine modulates gene expression patterns in monocyte
derived mature dendritic cells: implications for HIV-1 pathogenesis. Mol
Diagn Ther 10: 257–269.
14. Semple SJ, Patterson TL, Grant I (2003) Binge use of methamphetamine
among HIV-positive men who have sex with men: pilot data and HIV
prevention implications. AIDS Educ Prev 15: 133–147.
15. Chang L, Ernst T, Speck O, Grob CS (2005) Additive effects of HIV and
chronic methamphetamine use on brain metabolite abnormalities. Am J
Psychiatry 162: 361–369.
16. Riviere GJ, Gentry WB, Owens SM (2000) Disposition of methamphetamine
and its metabolite amphetamine in brain and other tissues in rats after
intravenous administration. J Pharmacol Exp Ther 292: 1042–1047.
17. Kleijmeer MJ, Raposo G, Geuze HJ (1996) Characterization of MHC class II
compartments by immunoelectron microscopy. Methods 10: 191–207.
18. Paludan C, Schmid D, Landthaler M, Vockerodt M, Kube D, et al. (2005)
Endogenous MHC class II processing of a viral nuclear antigen after
autophagy. Science 307: 593–596.
19. Lee HK, Lund JM, Ramanathan B, Mizushima N, Iwasaki A (2007)
Autophagy-dependent viral recognition by plasmacytoid dendritic cells.
Science 315: 1398–1401.
20. Talloczy Z, Virgin HW 4th, Levine B (2006) PKR-dependent autophagic
degradation of herpes simplex virus type 1. Autophagy 2: 24–29.
21. Talloczy Z, Jiang W, Virgin HW 4th, Leib DA, Scheuner D, et al. (2002)
Regulation of starvation- and virus-induced autophagy by the eIF2alpha
kinase signaling pathway. Proc Natl Acad Sci U S A 99: 190–195.
22. Melega WP, Cho AK, Harvey D, Lacan G (2007) Methamphetamine blood
PLoS Pathogens | www.plospathogens.org February 2008 | Volume 4 | Issue 2 | e28 0010
Methamphetamine Inhibits Immune Responseconcentrations in human abusers: application to pharmacokinetic model-
ing. Synapse 61: 216–220.
23. Cho AK, Melega WP, Kuczenski R, Segal DS (2001) Relevance of
pharmacokinetic parameters in animal models of methamphetamine
abuse. Synapse 39: 161–166.
24. Harris DS, Boxenbaum H, Everhart ET, Sequeira G, Mendelson JE, et al.
(2003) The bioavailability of intranasal and smoked methamphetamine.
Clin Pharmacol Ther 74: 475–486.
25. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, et al. (1996)
Striatal dopamine nerve terminal markers in human, chronic methamphet-
amine users. Nat Med 2: 699–703.
26. Karch SB, Stephens BG (2000) Toxicology and pathology of deaths related
to methadone: retrospective review. West J Med 172: 11–14.
27. Logan BK, Fligner CL, Haddix T (1998) Cause and manner of death in
fatalities involving methamphetamine. J Forensic Sci 43: 28–34.
28. Trombetta ES, Mellman I (2005) Cell biology of antigen processing in vitro
and in vivo. Annu Rev Immunol 23: 975–1028.
29. Riese RJ, Mitchell RN, Villadangos JA, Shi GP, Palmer JT, et al. (1998)
Cathepsin S activity regulates antigen presentation and immunity. J Clin
Invest 101: 2351–2363.
30. Eskelinen EL, Illert AL, Tanaka Y, Schwarzmann G, Blanz J, et al. (2002)
Role of LAMP-2 in lysosome biogenesis and autophagy. Mol Biol Cell 13:
3355–3368.
31. Peters PJ, Neefjes JJ, Oorschot V, Ploegh HL, Geuze HJ (1991) Segregation
of MHC class II molecules from MHC class I molecules in the Golgi
complex for transport to lysosomal compartments. Nature 349: 669–676.
32. Nishi T, Forgac M (2002) The vacuolar (Hþ)-ATPases–nature’s most
versatile proton pumps. Nat Rev Mol Cell Biol 3: 94–103.
33. Hurtado-Lorenzo A, Skinner M, El Annan J, Futai M, Sun-Wada GH, et al.
(2006) V-ATPase interacts with ARNO and Arf6 in early endosomes and
regulates the protein degradative pathway. Nat Cell Biol 8: 124–136.
34. Sulzer D, Maidment NT, Rayport S (1993) Amphetamine and other weak
bases act to promote reverse transport of dopamine in ventral midbrain
neurons. J Neurochem 60: 527–535.
35. Sulzer D, Sonders MS, Poulsen NW, Galli A (2005) Mechanisms of
neurotransmitter release by amphetamines: a review. Prog Neurobiol 75:
406–433.
36. Zwart W, Griekspoor A, Kuijl C, Marsman M, van Rheenen J, et al. (2005)
Spatial separation of HLA-DM/HLA-DR interactions within MIIC and
phagosome-induced immune escape. Immunity 22: 221–233.
37. Carballo E, Pitterle DM, Stumpo DJ, Sperling RT, Blackshear PJ (1999)
Phagocytic and macropinocytic activity in MARCKS-deﬁcient macrophages
and ﬁbroblasts. Am J Physiol 277: C163–C173.
38. Barnden MJ, Allison J, Heath WR, Carbone FR (1998) Defective TCR
expression in transgenic mice constructed using cDNA-based alpha- and
beta-chain genes under the control of heterologous regulatory elements.
Immunol Cell Biol 76: 34–40.
39. Mizushima N, Yamamoto A, Matsui M, Yoshimori T, Ohsumi Y (2004) In
vivo analysis of autophagy in response to nutrient starvation using
transgenic mice expressing a ﬂuorescent autophagosome marker. Mol Biol
Cell 15: 1101–1111.
40. Larsen KE, Fon EA, Hastings TG, Edwards RH, Sulzer D (2002) Methamphet-
amine-induced degeneration of dopaminergic neurons involves autophagy
and upregulation of dopamine synthesis. J Neurosci 22: 8951–8960.
41. Richards JR, Bretz SW, Johnson EB, Turnipseed SD, Brofeldt BT, et al.
(1999) Methamphetamine abuse and emergency department utilization.
West J Med 170: 198–202.
42. Bouvier G, Benoliel AM, Foa C, Bongrand P (1994) Relationship between
phagosome acidiﬁcation, phagosome-lysosome fusion, and mechanism of
particle ingestion. J Leukoc Biol 55: 729–734.
43. Cox D, Lee DJ, Dale BM, Calafat J, Greenberg S (2000) A Rab11-containing
rapidly recycling compartment in macrophages that promotes phagocy-
tosis. Proc Natl Acad Sci U S A 97: 680–685.
44. Enoch DA, Ludlam HA, Brown NM (2006) Invasive fungal infections: a
review of epidemiology and management options. J Med Microbiol 55: 809–
818.
45. Sun J, Soos T, Kewalramani VN, Osiecki K, Zheng JH, et al. (2006) CD4-
speciﬁc transgenic expression of human cyclin T1 markedly increases
human immunodeﬁciency virus type 1 (HIV-1) production by CD4þ T
lymphocytes and myeloid cells in mice transgenic for a provirus encoding a
monocyte-tropic HIV-1 isolate. J Virol 80: 1850–1862.
46. Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A (2006) New insights
into the antiviral effects of chloroquine. Lancet Infect Dis 6: 67–69.
47. Zhou D, Li P, Lin Y, Lott JM, Hislop AD, et al. (2005) Lamp-2a facilitates
MHC class II presentation of cytoplasmic antigens. Immunity 22: 571–581.
48. Dengjel J, Schoor O, Fischer R, Reich M, Kraus M, et al. (2005) Autophagy
promotes MHC class II presentation of peptides from intracellular source
proteins. Proc Natl Acad Sci U S A 102: 7922–7927.
49. Levitz SM, Harrison TS, Tabuni A, Liu X (1997) Chloroquine induces
human mononuclear phagocytes to inhibit and kill Cryptococcus neofor-
mans by a mechanism independent of iron deprivation. J Clin Invest 100:
1640–1646.
50. Harrison TS, Grifﬁn GE, Levitz SM (2000) Conditional lethality of the
diprotic weak bases chloroquine and quinacrine against Cryptococcus
neoformans. J Infect Dis 182: 283–289.
51. Hart PD, Young MR (1991) Ammonium chloride, an inhibitor of
phagosome-lysosome fusion in macrophages, concurrently induces phag-
osome-endosome fusion, and opens a novel pathway: studies of a
pathogenic mycobacterium and a nonpathogenic yeast. J Exp Med 174:
881–889.
52. Raposo G, Moore M, Innes D, Leijendekker R, Leigh-Brown A, et al. (2002)
Human macrophages accumulate HIV-1 particles in MHC II compart-
ments. Trafﬁc 3: 718–729.
53. Deneka M, Pelchen-Matthews A, Byland R, Ruiz-Mateos E, Marsh M (2007)
In macrophages, HIV-1 assembles into an intracellular plasma membrane
domain containing the tetraspanins CD81, CD9, and CD53. J Cell Biol 177:
329–341.
54. The Partnership for a Drug-Free America (2007) Partnership for a Drug-
Free America. Available: http://www.drugfree.org/. Accessed 20 September
2007.
55. Yin B, Loike JD, Kako Y, Weinstock PH, Breslow JL, et al. (1997)
Lipoprotein lipase regulates Fc receptor-mediated phagocytosis by macro-
phages maintained in glucose-deﬁcient medium. J Clin Invest 100: 649–657.
56. Diwu Z, Chen CS, Zhang C, Klaubert DH, Haugland RP (1999) A novel
acidotropic pH indicator and its potential application in labeling acidic
organelles of live cells. Chem Biol 6: 411–418.
57. Castellino F, Germain RN (1995) Extensive trafﬁcking of MHC class II-
invariant chain complexes in the endocytic pathway and appearance of
peptide-loaded class II in multiple compartments. Immunity 2: 73–88.
58. Casadevall A, Cassone A, Bistoni F, Cutler JE, Magliani W, et al. (1998)
Antibody and/or cell-mediated immunity, protective mechanisms in fungal
disease: an ongoing dilemma or an unnecessary dispute? Med Mycol 36
Suppl 1: 95–105.
PLoS Pathogens | www.plospathogens.org February 2008 | Volume 4 | Issue 2 | e28 0011
Methamphetamine Inhibits Immune Response